Suki et al. reviewed data from randomized trials and observational studies involving MASLD patients and concluded that SGLT2 inhibitor therapy reduces liver steatosis and improves non-invasive fibrosis markers [143]. This evidence concerns the gene SLC5A2 and fatty liver disease.